Acorda Therapeutics Inc., of Ardsley, N.Y., said it received a Paragraph IV certification advising that Actavis Laboratories FL Inc., a unit of Dublin-based Actavis plc, submitted an abbreviated new drug application to the FDA seeking permission to manufacture and market a generic version of multiple sclerosis drug Ampyra (dalfampridine) extended-release tablets 10 mg.